drugset
drugset / Trial / NCT00275106

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

NCT00275106 ↗

Phase 3 Terminated 600 enrolled Children's Cancer and Leukaemia Group European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · collab
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as prednisolone and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known whether prednisolone is more effective than dexamethasone when given together with combination chemotherapy in treating lymphoblastic lymphoma. PURPOSE: This phase III randomized clinical trial is studying prednisolone to see how well it works compared to dexamethasone when given together with combination chemotherapy in treating young patients with newly diagnosed lymphoblastic lymphoma.

Timeline

Start
2004-09
Primary completion
2009-12
Completion
2012-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule — Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule — Oral
Subject Methotrexate Small molecule — Intrathecal
Subject Prednisolone Other / unclassified — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Cytarabine Small molecule — Intravenous
Background Daunorubicin Small molecule — Intravenous
Background Doxorubicin Other / unclassified — Intravenous
Background Leucovorin Small molecule — Intravenous
Background Thioguanine Small molecule — Oral
Background Vincristine Small molecule — Intravenous
Background asparaginase Protein / enzyme biologic — Intravenous

Indications

lymphoma